ARCA Biopharma Announces AB201 Development Program For Treatment of COVID-19 Associated Coagulopathy

  • This topic is empty.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • 05/28/2020 at 12:07 pm #5335
    Colorado BioScience AssocationColorado BioScience Association
    Keymaster

    ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment for COVID-19 associated coagulopathy (CAC) and the related inflammatory response.

    Learn more.

  • Author
    Posts
Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.